Related Experiment Videos
Prostate cancer after heart transplantation: unicenter case-control study.
Siamak Mohammadi1, Giuseppe Silvaggio, Nicolas Bonnet
1Institute of Cardiology, Thoracic and Cardiovascular Surgery Department, La Pitié Hospital, Paris, France. siamakmohammadi@yahoo.com
Summary
Heart transplant recipients (HTR) show a high incidence of prostate cancer. Routine screening with prostate-specific antigen (PSA) testing is recommended for early detection and curative treatment, ensuring similar survival rates.
Area of Science:
- Oncology
- Transplant Surgery
- Urology
Background:
- An elevated incidence of prostate cancer has been observed in heart transplant recipients (HTR).
- This study investigates prostate cancer in HTR post-transplantation.
Purpose of the Study:
- To determine the prevalence, treatment, and outcomes of prostate cancer in HTR.
- To compare prostate cancer outcomes in HTR with a matched control group.
Main Methods:
- Retrospective review of patients undergoing heart transplantation.
- Systematic screening for prostate cancer using prostate-specific antigen (PSA) levels.
- Comparison with case-matched HTR without prostate cancer.
Main Results:
- 14 of 702 HTR were diagnosed with prostate cancer, with a median diagnosis time of 73 months post-transplant.
- All diagnoses were early-stage (
- 11 patients received curative treatment, and survival rates were similar between study and control groups, with one death attributed to prostate cancer.
Conclusions:
- Routine PSA screening is recommended for HTR to detect early-stage prostate cancer.
- Early detection facilitates curative treatment and maintains comparable survival rates to non-cancer HTR.
- Proactive screening can significantly improve outcomes for HTR diagnosed with prostate cancer.